Small ubiquitin‐related modifiers: A novel and independent class of autoantigens in primary biliary cirrhosis

Caroline Janka, Carlo Selmi, M. Eric Gershwin, Hans Will, Thomas Sternsdorf – 22 February 2005 – Serum autoantibodies against components of nuclear dots (anti‐NDs), namely PML and Sp100, are specifically detected in 20% to 30% of patients with primary biliary cirrhosis (PBC). Although anti‐ND antibodies are nonpathogenic, the mechanisms that lead to this unique reactivity are critical to understanding the loss of immune tolerance in PBC. Importantly, Sp100 and PML are both covalently linked to small ubiquitin‐related modifiers (SUMOs).

Hepatitis B virus pre‐S2 mutant upregulates cyclin A expression and induces nodular proliferation of hepatocytes

Hui‐Ching Wang, Wen‐Tsan Chang, Wen‐Wei Chang, Han‐Chieh Wu, Wenya Huang, Huan‐Yao Lei, Ming‐Derg Lai, Nelson Fausto, Ih‐Jen Su – 22 February 2005 – Naturally occurring mutants with a deletion in the pre‐S2 region of the large surface protein (ΔS2‐LHBs) are prevalent in serum and livers of patients with chronic hepatitis B virus (HBV) infection associated with cirrhosis. The ΔS2‐LHBs protein is retained in the endoplasmic reticulum (ER) and may induce ER stress. One interesting observation is the consistently clustered distribution of hepatocytes expressing ΔS2‐LHBs.

Acute phase HBV‐specific T cell responses associated with HBV persistence after HBV/HCV coinfection

Simona Urbani, Carolina Boni, Barbara Amadei, Paola Fisicaro, Simona Cerioni, Maria Antonietta Valli, Gabriele Missale, Carlo Ferrari – 22 February 2005 – To characterize acute‐phase hepatitis B virus (HBV)‐specific T cell responses associated with self‐limited and persistent HBV infections, we compared a patient with acute HBV/HCV coinfection, who was able to control HCV but developed chronic hepatitis B, with patients who resolved acute HBV infection spontaneously.

Non‐Hodgkin's lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection

Ann‐Sofi Duberg, Marie Nordström, Anna Törner, Olle Reichard, Reinhild Strauss, Ragnhild Janzon, Erik Bäck, Karl Ekdahl – 22 February 2005 – The aim of this study was to evaluate the association between hepatitis C virus (HCV) infection and non‐Hodgkin's lymphoma (NHL), multiple myeloma (MM), thyroid cancer (TC), chronic lymphatic leukemia (CLL), acute lymphatic leukemia (ALL), and Hodgkin's lymphoma (HL). A Swedish cohort of 27,150 HCV‐infected persons notified during 1990‐2000 was included in the study.

Wilson disease in septuagenarian siblings: Raising the bar for diagnosis

Aftab Ala, Jimo Borjigin, Arnold Rochwarger, Michael Schilsky – 22 February 2005 – Wilson Disease (WD) usually presents in the first decades of life, although rare patients have a later presentation. We report the clincial features, diagnostic evaluation, and outcome with treatment of two septuagenarian siblings evaluated as part of a research trial for treatment of neurological WD. The index case was a 72‐year‐old woman who suffered progressive neurological disability, then developed sub‐fulminant liver failure.

Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C

Alan Lee Rothman, Chihiro Morishima, Herbert L. Bonkovsky, Stephen J. Polyak, Ranjit Ray, Adrian M. Di Bisceglie, Karen L. Lindsay, Peter F. Malet, Ming Chang, David R. Gretch, Daniel G. Sullivan, Atul K. Bhan, Elizabeth C. Wright, Margaret James Koziel – 22 February 2005 – The relationships among host immune and viral factors and the severity of liver disease due to hepatitis C virus (HCV) are poorly understood. Previous studies have focused on individual components of the immune response to HCV, often in relatively small numbers of patients.

Fatigue of cholestasis and the serotoninergic neurotransmitter system in the rat

Turgay Çelik, M. Zafer Gören, Kubilay Çınar, Hakan Gürdal, F. Oğuz Önder, Akif Tan, Berna Terzioğlu, A. Mithat Bozdayı, Hakan Bozkaya, Özden Uzunalimoğlu, Cihan Yurdaydin – 22 February 2005 – Fatigue associated with cholestasis may impair health‐related quality of life. The pathogenesis of this symptom is largely unknown, but it has been suggested that central serotoninergic neurotransmission may be implicated and that serotonin 1A receptor agonists may yield improvement.

Subscribe to